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Abstract (150 words) 29 
Lysostaphin is a bacteriolytic enzyme targeting peptidoglycan, the essential component of the 30 
bacterial cell envelope. It displays a very potent and specific activity towards staphylococci, 31 
including methicillin-resistant Staphylococcus aureus (MRSA). Lysostaphin causes rapid cell 32 
lysis and disrupts biofilms, and is therefore a therapeutic agent of choice to eradicate 33 
staphylococcal infections. The C-terminal SH3b domain of lysostaphin recognizes 34 
peptidoglycans containing a pentaglycine crossbridge and has been proposed to drive the 35 
preferential digestion of staphylococcal cell walls. Here, we elucidate the molecular 36 
mechanism underpinning recognition of staphylococcal peptidoglycan by the lysostaphin 37 
SH3b domain. We show that the pentaglycine crossbridge and the peptide stem are recognized 38 
by two independent binding sites located on opposite sides of the SH3b domain, thereby 39 
inducing a clustering of SH3b domains. We propose that this unusual binding mechanism 40 
allows a synergistic and structurally dynamic recognition of S. aureus peptidoglycan and 41 
underpins the potent bacteriolytic activity of this enzyme.  42 
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Introduction 43 
Lysostaphin is a bacteriolytic enzyme produced and secreted by Staphylococcus simulans 44 
biovar staphylolyticus 1. This exotoxin has a potent activity against a wide range of 45 
staphylococci including the opportunistic nosocomial pathogen Staphylococcus aureus  2. It 46 
displays endopeptidase activity and cleaves the pentaglycine crossbridges present in the 47 
essential component of the bacterial cell wall (peptidoglycan), leading to rapid cell lysis. In S. 48 
simulans biovar staphylolyticus, immunity to lysostaphin is conferred by Lif, an aminoacyl 49 
transferase that introduces serine residues into peptidoglycan crossbridges 3. This modification 50 
dramatically reduces susceptibility to lysostaphin.  51 
Due to its powerful antistaphylococcal activity against both planktonic cells and biofilms 4, 52 
lysostaphin has been extensively studied as a therapeutic agent to treat infections caused by 53 
methicillin resistant S. aureus (MRSA) 5-11. Recent studies have reported the design of 54 
lysostaphin variants with a reduced antigenicity and enhanced therapeutic efficacy 12,13 as well 55 
as strategies to harness the bactericidal activity of this toxin 14-16. Collectively, the studies 56 
published have demonstrated that lysostaphin represents a credible therapeutic agent to combat 57 
staphylococcal infections, either alone or in combination with antibiotics 17. 58 
Lysostaphin is a modular hydrolase produced as a pre-proenzyme. It comprises a signal 59 
peptide, 15 N-terminal repeats of 13 amino acids, a catalytic domain with glycylglycyl 60 
endopeptidase activity and a C-terminal peptidoglycan binding domain of 92 residues 3. The 61 
specificity of lysostaphin towards staphylococci has been attributed to its binding domain, 62 
which recognizes pentaglycine crossbridges 18,19. Recent crystallographic studies have 63 
confirmed early models and showed that the pentaglycine stem is recognized by a shallow 64 
groove formed between strands β1-β2 and the RT loop, the binding specificity being essentially 65 
conferred by steric hindrance 20. Despite this exquisite recognition mechanism, the SH3b 66 
domain displays a very weak affinity for the pentaglycine stems and binding has been shown 67 
to be optimal with multimeric peptidoglycan fragments, suggesting a mechanism more 68 
complex than initially anticipated 20,21.  69 
Here, we combine NMR and X-ray crystallography to elucidate the mechanism underpinning 70 
the recognition of staphylococcal peptidoglycans by the lysostaphin SH3b domain. We show 71 
that the SH3b domain contains two binding sites located on opposite sides of the protein, 72 
allowing a mutually exclusive recognition of these two peptidoglycan moieties. The 73 
recognition of the pentaglycine crossbridge and the peptide stem is therefore shared by two 74 
independent SH3b domains, allowing protein clustering on the peptidoglycan. We propose that 75 
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the combination of low affinity and high off-rate binding results in a synergistic and structurally 76 
dynamic binding that is particularly suitable for the recognition of non-contiguous epitopes of 77 
mature, physiological peptidoglycan. This unusual mechanism underpins the potent activity of 78 
lysostaphin and its capacity to punch holes in the cell walls to cause rapid cell lysis. 79 
  80 
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Results 81 
 82 
NMR analysis of SH3b-peptidoglycan interactions 83 
We sought to investigate the mechanism underpinning SH3b-PG interaction using NMR 84 
titrations with a panel of ligands of increasing complexity. Six ligands were produced, either 85 
by solid-phase synthesis or purified from S. aureus PG following digestion by hydrolytic 86 
enzymes (Supplementary Fig. 1). The ligands tested corresponded to a tetrasaccharide 87 
(GlcNAc-MurNAc- GlcNAc-MurNAc; GMGM), a pentaglycine crossbridge (GGGGG; G5), 88 
a tetrapeptide stem (AγQKA; P4), a tetrapeptide with the pentaglycine as a lateral chain 89 
(AγQK[GGGGG]A; P4-G5), a disaccharide-peptide dimer (GlcNAc-MurNAc-90 
AγQK[GGGGG]AA- GlcNAc-MurNAc-AγQK[GGGGG]A; (GM-P4-G5)2) and the peptide 91 
AγQK[GGGGG]AA-AγQKA (P5-G5-P4) containing two peptide stems crosslinked via a 92 
single pentaglycine crossbridge.  93 
Complete resonance assignment of the doubly labelled SH3b domain was obtained using 94 
standard triple resonance experiments (Supplementary Fig. 2).The six ligands were used to 95 
measure chemical shift perturbations (CSPs) associated with main-chain and side-chain amides 96 
(Supplementary Fig. 3 and Supplementary Table 1). 97 
In agreement with previous studies, our results showed that pentaglycine (G5) peptides interact 98 
with several residues located in a narrow cleft corresponding to the binding groove originally 99 
proposed for Staphylococcus capitis ALE-1, a close homolog of Lss. These included residues 100 
N405 to Y411, T429, G430, M453, D456 and Y472 (Fig. 1a, Supplementary Fig. 3a). CSPs of 101 
the signals corresponding to SH3b residues following addition of this ligand indicated a fast 102 
exchange rate with a weak binding affinity in the millimolar range (KD=890 ± 160µM).  103 
S. aureus peptidoglycan is highly crosslinked and therefore contains mostly tetrapeptide stems 104 
(P4). The SH3b domain bound to P4 peptides with a fast exchange rate and a low affinity 105 
(KD=963 ± 198µM), suggesting that this minimal ligand (like the G5 peptide) is not the 106 
complete PG motif recognised by the SH3b domain. Surprisingly, residues presenting 107 
pronounced chemical shifts upon binding to the P4 ligand were located on the side of the 108 
protein opposite to the G5 binding cleft (e.g., N421, I425, A443, V440; Fig. 1b and 109 
Supplementary Fig. 3b). Residue R427 side chain also showed a significant CSP. Two 110 
hydrophobic residues presenting relatively large CSPs were buried in the structure, suggesting 111 
that they were not directly in contact with the P4 ligand (V461 and L473). This observation 112 
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implies that whereas binding at G5 is fairly rigid lock-and-key, binding at P4 is more of an 113 
induced fit interaction, with adaptation of the protein to fit its ligand. 114 
As expected, a tighter binding was observed for two PG monomer ligands made of the 115 
tetrapeptide stem with a pentaglycine lateral chain alone (P4-G5; KD = 98 ± 42 µM). The most 116 
prominent CSPs corresponded to residues previously identified with the simple ligands G5 and 117 
P4 in both cases (Fig. 1b,c). Several residues broadened and disappeared with the P4-G5 ligand 118 
(N405, I425, V461, G462, Y472 and L473), indicating a slow to medium exchange rate 119 
(Supplementary Fig. 3c). Titrations with a synthetic tetrasaccharide (GlcNAc-MurNac)2 120 
revealed no interactions between the protein and the synthetic disaccharides, suggesting that 121 
the sugars do not play a key role in the recognition of peptidoglycan by the SH3b domain. 122 
Next, we studied the binding of SH3b domain to dimeric PG fragments made of two peptide 123 
stems crosslinked by a pentaglycine chain. One of these ligands contained a single pentaglycine 124 
chain (P5-G5-P4), whilst the other had two (GM-P5-G5-GM-P4-G5). The largest CSPs 125 
associated with binding were those previously identified with simpler ligands (G5 and P4) (Fig. 126 
1e,f and Supplementary Fig. 3e,f). The CSPs corresponding to the recognition of the P4/P5 or 127 
G5 moieties were typical of a fast exchange rate, with an affinity of 100  ± 34µM for the P5-128 
G5-P4 ligand. In the case of the most complex ligand (GM-P5-G5-GM-P4-G5), we could not 129 
determine any binding affinity since the protein started to precipitate in the presence of 4 130 
equivalents of ligand resulting in the disappearance of the signals. One surface residues (W489) 131 
located close to residues binding the peptide stem only displayed CSPs with dimeric ligands. 132 
Interestingly, the CSPs observed for the larger ligands had fewer large changes than were seen 133 
for the simpler ligands (Supplementary Fig. 3). 134 
Collectively, NMR titrations suggested that the SH3b domain recognises both the PG peptide 135 
stems and crossbridges via distinct sets of residues located on opposite sides of the protein 136 
surface. 137 
 138 
 139 
Structure of the SH3b-S. aureus PG peptide stem complex 140 
We attempted to co-crystallize the SH3b domain with a branched P4-G5 ligand and were 141 
successful in obtaining crystals that diffracted to 1.4 Å resolution. Our initial expectation was 142 
to observe this ligand binding to the surface of a single SH3b domain but upon solving the 143 
structure it was apparent that the G5 was recognized by one domain and P4 by another 144 
(symmetry-related copy) as shown in Fig. 2. The 1.4 Å high resolution, synchrotron set is able 145 
to trace three of the P4 units (γQKA representing units 2-4) and a lower 2.5 Å home source set 146 
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is essentially identical but allows tracing of the full P4 ligand (AγQKA). In our structures, the 147 
pentaglycine bridge sits identically to that of other SH3b structures (5LEO), but then projects 148 
the crossbridge link (K to G5) and stem peptide (AγQKA) into a pocket located on the opposite 149 
side of a second SH3b monomer (Fig. 2a-c). The two SH3 domains make no strong interactions 150 
with one another, but display a shape/surface complementarity that allows for close contact 151 
around the shared ligand. 152 
The P4 and G5 components of the ligand are at approximately 90˚ angles to one another, and 153 
the carbon atoms of the K3 sidechain make favourable contacts with the hydrophobic 154 
sidechains of Y407, T422’, I424’ and W489’ (prime used to denote opposing SH3b). Units one 155 
to three of the P4 peptidoglycan stem display a linear β-like conformation, with peptide bonds 156 
hydrogen-bonding to residues from both SH3b domains: γQ2 NH to carbonyl of K406, K3 NH 157 
to carbonyl of D423’, and K3 CO to NH of I425’. This arrangement makes for much stronger 158 
contacts of the SH3b domains to P3/P4 in comparison to P1/P2, and would place the attached 159 
physiological peptidoglycan saccharide units at the edge of both monomers. There is a clearly 160 
defined pocket for the terminal D-Ala 4 (Fig. 2d), with the COO- group making a salt-bridge 161 
to the sidechain of R427’, and a hydrophobic pocket comprised of I424’, I425’, R433’, H458’, 162 
W460’, P474’ and W489’ surrounding the methyl sidechain of the substrate. Sequence and 163 
structure alignments between lysostaphin SH3b (SH3_5) and other proteins indicate that the 164 
P4 D-Ala-carboxylate pocket is likely a conserved feature of wider superfamily members 165 
(Supplementary Fig. 4), with relevance for both SH3_3 and SH3_4 subgroups. There are no 166 
current structures for the latter, but the two SH3_4 domains of Clostridium phage lysin 167 
phiSM101 each have a carboxylate ligand bound at this position, suggesting an important role 168 
for the residues equivalent to lysostaphin R427 22. 169 
 170 
Mutational analysis of the binding activity 171 
We sought to confirm the contribution of the SH3b residues identified by NMR and X-ray 172 
crystallography to the recognition of the crossbridge (G5) and peptide stem (P4) ligands. Six 173 
single-site substitution mutant domains were produced and analysed by NMR (N405A, 174 
M453A, Y472S, I425A, R427M, W489L). 15N HSQC spectra of all mutant domains revealed 175 
that these were properly folded, allowing us to measure CSP values in the presence of the 176 
maximum concentration of ligand previously used (32 equivalents). As expected, all mutations 177 
were associated with a reduction in CSPs when compared to the wild-type domain 178 
(Supplementary Fig. 5). We characterised the reduction in binding affinity using a figure of 179 
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residual binding, which is defined as the ratio of chemical shift changes of mutant to WT, 180 
averaged over all amino acids. Given the weak binding affinities, and the fact that the protein 181 
concentration is always lower than the affinity, these correspond roughly to the expected 182 
reduction in affinity. Domains with mutations in the residues involved in the interaction with 183 
G5 still retained a relatively high residual binding, the N405A mutation having the most 184 
pronounced effect (16% residual binding for the N405A mutant, 55.5% for M453A and 24.6% 185 
for Y472S). Whilst the I425 still displayed 29.4% residual binding, the mutations R427M and 186 
W489L had a major impact on binding to the P4 ligand (1.6% and 6.6% residual binding, 187 
respectively). These results confirmed the contribution of the residues identified by NMR and 188 
crystallography to the binding of minimal ligands. The limited impact of most of the mutations 189 
studied on binding is in agreement with the X-ray and NMR results which revealed that the 190 
recognition of peptidoglycan fragments by SH3b domains relies on a complex network of 191 
interactions. 192 
 193 
Binding of SH3b derivatives to purified PG sacculi 194 
Due to the labour-intensive nature of NMR analyses and the fact that these analyses are limited 195 
to study interactions with soluble substrates, we designed a quantitative in vitro binding assay 196 
with peptidoglycan sacculi which represent the natural substrate of lysostaphin. The SH3b 197 
domain was fused to the monomeric fluorescent protein mNeonGreen 23 to follow binding in 198 
the presence of increasing amount of peptidoglycan (Fig. 3 and Supplementary Table 2). 199 
Recombinant proteins were purified using two chromatography steps including metal affinity 200 
and gel filtration. As a first step we measured the binding of SH3b-mNeonGreen fusions to 201 
peptidoglycan purified from the WT, femB and femAB mutants (containing five, three and one 202 
glycine residue in crossbridges, respectively) (Fig. 3a and Supplementary Fig. 6). As expected, 203 
binding occurred in a dose-dependent manner and binding to the femB mutant was clearly 204 
reduced (1.71-fold change), whilst a more drastic reduction in binding was observed with the 205 
femAB mutant (2.20-fold change). The residual, dose-dependent binding to the fem mutant 206 
peptidoglycans is in agreement with our identification of a second site recognizing the peptide 207 
stems. Fifteen recombinant fusions with mutations in residues previously identified were 208 
purified and their binding activity was measured (Fig. 3b,c and Supplementary Fig. 6). Most 209 
of the mutations clearly impaired binding to peptidoglycan to a level similar to the level of 210 
binding displayed by the WT-mNeonGreen fusion to the femB peptidoglycan. The biggest 211 
impact on binding was observed with mutations R427M and W489L impairing the recognition 212 
of peptide stems (2.47- and 2.18-fold changes as compared to the WT, respectively). These 213 
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results therefore confirmed the role of the residues identified by NMR and X-ray 214 
crystallography and provided the first evidence that peptide stem recognition by the lysostaphin 215 
SH3b domain is critical for binding. 216 
 217 
Impact of SH3b mutations on Lss activity 218 
The SH3b mutations previously described (Supplementary Fig. 6) were introduced into the 219 
mature lysostaphin enzyme. Recombinant proteins were purified and serial 2-fold dilutions 220 
were spotted on agar plates containing autoclaved S. aureus cells as a substrate (Supplementary 221 
Fig. 7). The enzymatic activity was detected as a clearing zone resulting from the solubilisation 222 
of S. aureus cell walls. Four independent series of protein purifications were carried out, each 223 
including a wild-type lysostaphin protein. One lysostaphin mutant (Lss_M453A) showing an 224 
aberrant circular dichroism spectrum could not be analysed; mutant R427M was also excluded 225 
from the study as it did not bind to the nickel column. Amongst all the mutations tested, Y472S 226 
and W489L led to the most important effects observed (9-fold decrease), whilst all the others 227 
had only a limited impact. These results were in line with the binding assays, indicating that 228 
no single mutation abolished enzymatic activity and supported our results indicating that the 229 
recognition of the peptide stem is equally, if not more, important for binding and activity as is 230 
binding to the pentaglycine bridge.   231 
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Discussion 232 
The crystal structure reported here shows that SH3b has two well-defined binding sites for S. 233 
aureus peptidoglycan: a narrow groove that accommodates the G5 lateral chain, with a tightly 234 
defined geometry and thus little tolerance for amino acid variants; and a more open site for the 235 
P4 peptide stem. One might therefore expect that the specificity for S. aureus PG arises entirely 236 
from the G5 site, which should be critical for binding. This is not what is indicated by the other 237 
results reported here.    238 
The interpretation of CSPs, and of the affinities determined by fitting CSPs to a saturation 239 
curve, is more complex than may at first appear. A perturbation of an 15N or 1H nuclear 240 
shielding is typically caused by a change in the chemical environment at the nucleus, for 241 
example due to a change in hydrogen bonding or a change in the position of neighboring 242 
functional groups. Hydrogen bonding is highly directional, implying that an increased mobility 243 
of a ligand within its binding site will result in significantly smaller CSPs. Increased mobility 244 
will not necessarily result in weaker overall binding, because the loss in enthalpy due to a 245 
weaker time-averaged hydrogen bond can easily be compensated by a gain in entropy. Smaller 246 
CSPs can therefore indicate a more dynamic binding interaction, rather than simply weaker 247 
binding. This phenomenon matches what is observed here (Supplementary Fig. 3). With a 248 
simple G5 or P4 ligand that binds in a single site, there are some large CSPs, clearly defining 249 
the location of the site (Supplementary Fig. 3a,b). With larger ligands, although the affinity is 250 
stronger (implying cooperative binding at both sites, see below), there are fewer large CSP 251 
values. The most obvious interpretation is that within each site the ligand has greater mobility, 252 
presumably because the physical linkage between the G5 and P4 groups prevents the larger 253 
ligands from binding optimally in both sites simultaneously. 254 
There have been many analyses published of binding affinities of ligands that interact via two 255 
different sites. A powerful approach is the concept of effective concentration 24,25. Consider a 256 
ligand L1-L2 that binds at two sites, R1 and R2, with a flexible linker between L1 and L2 (Fig 257 
4a). If the ligand detaches from site R2, then the rate at which L2 rebinds at R2 is given by 258 
kon×[L2]eff, where kon is the rate constant for binding and [L2]eff is the effective concentration 259 
of L2 at the R2 binding site (Fig 4b). For a short linker with optimal length and geometry, 260 
[L2]eff can be orders of magnitude larger than [L2], leading to much stronger binding than 261 
would be seen in the absence of L1 (because the overall affinity for L2 is equal to the off-rate 262 
divided by the on-rate, and we can assume that the off-rate is unaffected by the presence of the 263 
linker): in other words, to cooperative binding, such that the affinity for the intact ligand L1-264 
L2 is much stronger than the affinity for L1 or L2 alone. Conversely, if the linker is too short 265 
Peptidoglycan recognition by lysostaphin 
11 
 
(Fig 4c), then L2 is unable to reach R2, and [L2]eff is smaller than [L2], leading to a complete 266 
lack of cooperativity. If the binding sites R1 and R2 allow for some flexibility in geometry, 267 
then we may have a situation as shown in Fig 4d, where binding of the ligand can be achieved 268 
by allowing some mobility in the bound conformation at the cost of suboptimal binding 269 
geometry. The cooperativity will not be as great as it would be with ideal geometry and thus 270 
the affinity will be stronger but not by a large amount. This appears to be exactly the situation 271 
observed here: affinity is 10× stronger, but CSPs are smaller. Furthermore, single site mutations 272 
have relatively little effect on the affinity or on enzymatic activity, suggesting that the exact 273 
shape or complementarity of the binding site is relatively unimportant, consistent with this 274 
model.  275 
It is a legitimate question to ask why SH3b should have evolved separate binding sites for G5 276 
and P4, but located on the protein surface in such a way that simultaneous binding to both sites 277 
is not possible. What is the biological advantage? Our data, and the interpretation derived here, 278 
provide suggestions. The function of the SH3b domain is to attach lysostaphin to PG, in such 279 
a way as to increase access of the catalytic domain to its G5 substrate. It is therefore not 280 
desirable for the affinity for PG to be too strong, otherwise SH3b would detach too slowly and 281 
not allow the catalytic domain to move from one G5 substrate to another. A good solution is to 282 
have two binding sites, both with weak affinity and thus rapid off-rates, and organised so as to 283 
provide a moderate degree of cooperativity in binding to the complex substrate. This allows 284 
the protein to ‘walk’ around the PG surface, continually keeping at least one site bound, but 285 
permitting rapid searching on the PG surface. A very similar solution has been adopted by a 286 
number of cellulases, which have two different cellulose binding domains arranged in tandem 287 
26-29
.  288 
A comparison of interactions at the two sites with different ligands (Fig. 1) suggests that the 289 
larger ligands have weaker interactions at the G5 site, since the G5 interactions (red) decrease 290 
more than do the P4 interactions (green). This result is at first sight counterintuitive, because 291 
the lysostaphin catalytic domain specifically targets G5. However SH3b should not bind too 292 
tightly to G5, because otherwise it would block access of the catalytic domain. It therefore 293 
makes sense for the larger (and thus more cell-wall-like) fragments to favor binding of the 294 
peptide stem, as long as some specificity for G5 is maintained, and as long as SH3b is not 295 
locked into binding at any particular location. We may therefore describe the role of SH3b as 296 
to contribute to the initial (weak) binding of the enzyme on the PG surface. This conclusion is 297 
also consistent with the observation that the mutations more critical to binding affinity are 298 
found in the P4 site, not the G5 site. Surprisingly, and in agreement with this result, the SH3b 299 
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domain still binds in a dose-dependent manner to the femAB peptidoglycan, containing 300 
crossbridges made of a single glycine residue. This suggests that the recognition of the 301 
pentaglycine stem is not essential for the binding of the enzyme with its substrate. Based on 302 
this result, it is tempting to hypothesize that the catalytic activity of lysostaphin rather than the 303 
binding itself is the major determinant for the specific hydrolysis of staphylococcal 304 
peptidoglycan. In Staphylococcus carnosus, the femB mutation is associated with a 3000-fold 305 
increase in the MIC values for lysostaphin from 0.01 to 32 µg/ml 30. Given the limited impact 306 
of the SH3b mutations on binding, this result suggests that the high resistance to lysostaphin in 307 
the femB mutant is not caused by the slight difference in binding activity of the penta- vs tri-308 
glycine interpeptide bridge, but is mainly due to the decreased enzymatic activity of 309 
lysostaphin. 310 
The networks of contacts between ligand and two sets of SH3 domains strongly suggest that 311 
our two-site model for P4-G5 (and therefore true, complex sacculus ligand) is physiologically 312 
relevant. The observed pocket for the terminal P4 D-Ala is highly complementary in both shape 313 
and contact type; a lack of adjoining pocket for a second D-Ala of a pentapeptide is in keeping 314 
with the dominance of tetrapeptides in staphylococcal peptidoglycan 31. Residues responsible 315 
for P4 recognition are conserved in several homologues present in the PDB despite the relative 316 
low sequence identity across the entire domain – S. capitis ALE-1 (code 1R77, 83% sequence 317 
identity, 19), Staphylococcus phage GH15 lysin (2MK5, 49%, 32) and phage phi7917 lysin 318 
(5D76, 30%, unpublished). These related structures have features that validate our 319 
identification of the P4 binding site (overlays shown in Supplementary Fig. 4): in ALE-1 a 320 
purification tag places a lysine in an identical position to the K3 crosslink, and in phi7917 a 321 
muramyldipeptide cleavage product has bound in this region. Our identification of a “second” 322 
binding site supplementing the “traditional” pentaglycine cleft may have implications for other 323 
SH3b and SH3-like domains that are used in varying architectures to recognize peptidoglycan 324 
in organisms that do not utilize the G5 crossbridge. 325 
No major difference exists between the structure of the SH3b domain in its apo form (4LXC) 326 
and in complex with the P4-G5 ligand (this work), suggesting that the ligand displays a 327 
dynamic structure to “fit” within the binding clefts present on the SH3b domain. Previous NMR 328 
studies support this idea and have shown that the D-Lac, L-Ala, and D-Glu adopt a limited 329 
number of conformers, whereas the L-Lys-D-Ala termini are disordered (with no NOE contacts 330 
observed 33). Further relaxation measurements using the P4-G5 ligand could be carried out to 331 
test this hypothesis but it appears difficult to extrapolate relaxation experiments to a complex 332 
molecule such as peptidoglycan. 333 
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The data presented here provide an explanation as to why the binding activity of the SH3b 334 
domain of lysostaphin is not affected by exogenous pentaglycine or its own catalytic 335 
products 21; our model suggests that the muropeptide interactions are only satisfied when 336 
presented by non-contiguous epitopes of mature, physiological peptidoglycan. The location of 337 
these sites on different faces of the SH3b molecule ensures that both are unlikely to be 338 
contacted by a soluble, torsionally less-restricted fragment. We hypothesize that this will be an 339 
excellent method for processive degradation of the peptidoglycan.  340 
The structure of the SH3b domain in complex with the P4-G5 peptide shed light on the NMR 341 
analyses previously published 34 and those described in this manuscript, revealing the existence 342 
of two independent binding sites on opposite sides of the SH3b domain. The binding 343 
mechanism described here is consistent with the formation of large protein aggregates during 344 
titration with complex PG fragments. Recognition of the same PG peptide stem by independent 345 
SH3b domains (referred to as “clustering”) leads to an effective increase in enzyme 346 
concentration at the cell surface. In agreement with this hypothesis, the direct observation of 347 
S. aureus cell wall digestion by lysostaphin using atomic force microscopy revealed the 348 
existence of nanoscale perforations that precede cell lysis 35. 349 
  350 
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Materials and methods 351 
 352 
Bacterial strains, plasmids and growth conditions.  353 
Bacterial strains and plasmids used in this study are described in Supplementary Table 3. E. 354 
coli Lemo21 (DE3) and NEB5α strains were grown at 37°C in Luria-Bertani (LB) or M9 355 
minimal medium containing 1 g/L of 15NH4Cl (and 2 g/L 13C6-glucose where necessary), 356 
supplemented with ampicillin at a concentration of 100 µg/ml.  357 
 358 
Construction of recombinant plasmids for protein production. 359 
Both plasmids expressing the full length lysostaphin (pET-Lss) and the SH3b domains with a 360 
non-cleavable N-terminal His-tag for NMR studies (pET-SH3b) have been previously 361 
described 36,37. The plasmid encoding the SH3b-mNeonGreen fusion (pET-SH3b-NG) was 362 
constructed by Gibson assembly using a DNA synthetic fragment (Integrated DNA 363 
Technology) cloned into the vector pET2818 cut with NcoI and BamHI. Plasmid pET-SH3b-364 
TEV used to produce the SH3b domain without a tag for X-ray crystallography was constructed by 365 
Gibson assembly using a synthetic DNA fragment (Integrated DNA Technology) cloned into 366 
pET2817 digested with NcoI and BamHI. The amino acid sequences of the wild-type 367 
recombinant proteins are described in Supplementary Fig 8. 368 
 369 
Site-directed mutagenesis. 370 
Mutagenesis of plasmids pET-SH3b and pET-Lss was performed using the GeneArt® Site-371 
Directed Mutagenesis System (Thermo Fisher Scientific). All primers used in this study are 372 
described in the Supplementary Table 4. The same pair of oligonucleotides was used to 373 
introduce mutations in both plasmids, except for mutations N405D and W489L which required 374 
distinct pairs of oligonucleotides to build mNeonGreen fusions and lysostaphin mutants. 375 
 376 
Purification of recombinant Lss protein and Lss-SH3b protein domains.  377 
Cells were grown to an optical density at 600nm (OD600) of 0.7 in LB or M9 media for NMR 378 
analyses and protein production was induced by the addition of 1 mM IPTG. After 4h, induced 379 
cells were harvested and resuspended in buffer A (50 mM Tris-HCl, 500m M NaCl, pH 8.0) 380 
and crude lysates were obtained by sonication (3 × 30s, 20% output; Branson Sonifier 450). 381 
Soluble proteins were loaded onto a HiTrap IMAC column (GE Healthcare, Uppsala, Sweden) 382 
charged with Ni2+ or Zn2+ ions for SH3b (alone or fused to mNeonGreen) and full-length 383 
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lysostaphin, respectively. His-tagged proteins were eluted with a 20 column volume linear 384 
gradient of buffer B (500 mM imidazole, 50 mM Tris-HCl, 500 mM NaCl, pH 8.0). 385 
Recombinant His-tagged proteins were concentrated and purified by size-exclusion 386 
chromatography on a Superdex 75 HR column (GE Healthcare, Uppsala, Sweden). For NMR 387 
experiments, proteins were purified using 50 mM Na2HPO4 (pH 6.0). All purified proteins were 388 
analysed by SDS-PAGE.  389 
For crystallography experiments, the SH3b domain was produced using plasmid pET-SH3b-TEV. 390 
The N-terminal tag was removed using recombinant TEV protease (0.5 mg of TEV per mg of 391 
SH3b protein). Digestions were performed at 37°C overnight in buffer C (150 mM NaCl, 50 392 
mM Tris-HCl, pH 8.35). Following digestion, proteins were loaded onto a HiTrap IMAC 393 
column, and cleaved SH3b proteins were recovered in the flow through. Proteins 394 
concentrations were determined using absorbance at 280 nm.  395 
The characterization of all recombinant proteins is described in the supplementary information 396 
section (Supplementary Fig. 8-12). 397 
 398 
Purification of S. aureus PG sacculi 399 
PG sacculi were isolated from exponentially growing S. aureus cells as previously described 400 
38
.  Pure PG was freeze-dried and resuspended at a final concentration of 25 mg/ml.  401 
 402 
Peptidoglycan digestions for NMR titration assays  403 
S. aureus PG was digested with mutanolysin (Sigma). To purify PG dimers (GM-P5-G5-GM-404 
P4-G5), 180 mg of PG were digested with 2.5 mg of mutanolysin in a final volume of 5 ml 405 
using 20 mM phosphate buffer (pH 6.0). After overnight incubation the enzyme was heat-406 
inactivated. Half of the sample was used to purify dimers. The pH of the other half of digestion 407 
was adjusted to 7.5 and it was further digested with 2 mg of EnpA to generate disaccharide-408 
peptides. EnpA was heat-inactivated. 409 
 410 
Purification of peptidoglycan fragments by rp-HPLC  411 
Prior to rp-HPLC analysis and fractionation, soluble peptidoglycan fragments were reduced 412 
with sodium borohydride to eliminate double peaks corresponding to the α-and β-anomers as 413 
previously described 38. Fractionation of material corresponding to the digestion of 50 mg of 414 
PG was carried out on a Hypersil GOLD aQ column (C18; 21 × 250 mm, Thermo Scientific) 415 
and separated at a flow rate of 10 ml/min using 10 mM ammonium phosphate (pH 5.5) as a 416 
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mobile phase (buffer A). After a short isocratic step (2 column volumes), PG fragments were 417 
eluted with a 15 column volume methanol linear gradient (0 to 30%) in buffer A. Individual 418 
peaks were collected, freeze-dried and analysed by mass spectrometry. The fractions 419 
corresponding to the major dimer (GM-P5-G5-GM-P4-G5) were desalted by HPLC using a 420 
water-acetonitrile gradient, freeze-dried and resuspended in MilliQ water. 421 
 422 
Production of peptidoglycan fragments by chemical synthesis 423 
The tetrasaccharide (GMGM) was described previously 39. All peptides and branched peptides 424 
(>95% purity) were purchased from Peptide Protein Research Ltd. (UK) Purity was assessed 425 
by HPLC and mass spectrometry. The characterization of all ligands is described in the 426 
supplementary information section. The pentaglycine peptide was purchased from SIGMA 427 
Aldrich (ref. G5755). 428 
 429 
 430 
Crystallography and structure determination 431 
Crystallisation was initiated via standard screening in sitting drop 96-well clover-leaf 432 
crystallography trays at 18 mg/ml with 3.41 mM AγQK[GGGGG]A in a 1:2 drop ratio of screening 433 
agent to protein solution. The trays were incubated at 18 °C. Tetragonal bipyramidal crystals 434 
formed within the first 48 hours in 100 mM Bis-tris pH 5.5, 25% (w/v) poly-ethylene glycol 3350 435 
and 200 mM ammonium sulphate.  436 
Crystals were cryo-protected using the above conditions (inclusive of AγQK[GGGGG]A to 437 
maintain the ligand:protein complex), and an additional 20% v/v ethylene glycol. Two datasets 438 
were collected (Supplementary Table 5): a high resolution set at the I03 beamline, Diamond Light 439 
Source, Oxford, and a second set on a Rigaku Micromax home source. Data were processed with 440 
XiaII/XDS 40. The B-factors for the high-resolution set are higher than expected, but match that 441 
of the Wilson B, and the dataset has a normal intensity distribution. An initial model was solved 442 
using the existing apo structure 5LEO 20 as a molecular replacement model in PHASER 41, and the 443 
corresponding structure autobuilt using PHENIX 42, with the ligand added via visual inspection of 444 
the difference map. The structure was updated and refined using COOT 43, PHENIX 42 and PDB-445 
redo 44, resulting in a final structure with an R/Rfree of 19.9%/23.0%.  446 
 447 
NMR experiments 448 
NMR experiments were conducted on Bruker Avance I 800 and DRX-600 spectrometers at 449 
298K. 2D NHSQC experiments were carried out using the b_hsqcetf3gpsi pulse program 450 
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(Bruker) with relaxation delay 1 s, 128 complex increments (ca. 1 h 18 m per spectrum). Lss-451 
SH3b proteins were quantified by measuring the absorbance at 280 nm and adjusted to a 452 
concentration of 60 µM in 50 mM Na2HPO4 (pH 6.0). All ligands were quantified by NMR 453 
based on the intensity of methyl protons using trimethylsilylpropanoic acid (TSP) as a standard. 454 
15N HSQC experiments and chemical shift perturbation (CSP) analyses were performed as 455 
previously described 39. 456 
 457 
PG binding assays 458 
The PG binding activity of SH3b domains was studied using in-gel fluorescence. Protein 459 
amounts equivalent to 3 µg of the wild-type recombinant SH3b-mNeonGreen were adjusted 460 
based on the fluorescence intensity of the bands corresponding to the full length proteins. 461 
Following incubation in the presence of increasing amounts of PG (0-400 µg) in a final volume 462 
of 40 µl for 20 min at room temperature, PG and bound proteins were pelleted at 17,000 × g 463 
for 5 minutes. Twenty µl of supernatant corresponding to unbound proteins were loaded on an 464 
SDS-PAGE and scanned using a BioRad Chemidoc XRS+ system. Fluorescence intensity was 465 
quantified using the ImageJ software. The percentage of binding was determined using the 466 
signal intensity measured in the absence of PG as a reference. 467 
 468 
Lysostaphin activity assays 469 
S. aureus SH1000 45 was grown to an optical density OD600 of 1.0. Cells were harvested, 470 
resuspended in distilled water, autoclaved and incorporated in agar plates at a final OD600 of 471 
0.5. Five µl corresponding to serial dilutions of the recombinant lysostaphin proteins were 472 
spotted on the plates containing autoclaved cells as a substrate and incubated overnight at 473 
37 °C. Lytic activities were detected as clearing zones and compared by determining the lowest 474 
amount of enzyme giving a detectable digestion of the substrate 475 
 476 
Data availability 477 
Structural data have been deposited in the Protein DataBank (PDB) with coordinate accession 478 
numbers 6RK4 (high-resolution set) and 6RJE (home source set). All other data generated or 479 
analyzed during this study are included in this published article (and its supplementary 480 
information files) or are available from the corresponding authors on reasonable request.” 481 
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Figure legends 603 
 604 
Figure 1. Mapping the interaction surface of the SH3b domain with synthetic S. aureus 605 
PG fragments 606 
For each NMR titration, the average CSP was calculated and two-fold average CSP was chosen 607 
as a threshold to identify surface residues interacting with ligands. The residues interacting 608 
with the pentaglycine crossbridges are highlighted in red, those interacting with the peptide 609 
stem in green. Interaction maps corresponding to six ligands are shown. a, G5 peptide; b, P4; 610 
c, P4-G5; d, P5-G5-P4; f, GM-P5-G5-GM-P4-G5.  Titrations confirmed the existence of a 611 
narrow cleft previously proposed to bind the PG crossbridges 19 and recently shown to interact 612 
with pentaglycine 20. They also revealed a set of residues interacting with the peptide stem, 613 
located on the face of the protein opposite to the G5 binding cleft.  614 
 615 
Figure 2. Structure of lysostaphin SH3b in complex with the P4-G5 ligand 616 
The SH3b domain and a symmetry-related partner are coloured white and blue, respectively; 617 
ligand is coloured by atom type, with P4 C atoms green and G5 C atoms pink. a, protein fold 618 
with termini labelled, and two representations (fold and ligand in ribbon/stick and surface 619 
formats). b, Co-crystal structure showing the SH3b:ligand shape complementarity. c, Rotated 620 
view of a single SH3b domain showing the interaction with the P4 ligand (blue, with peptide 621 
units labelled 1-4). d, experimental 2Fo-Fc difference map contoured at 1 σ for different 622 
regions of the bound ligand, with selected interacting residues in stick form. The L-Ala 1 end 623 
panel is from the 2.5 Å dataset, others are from the 1.4 Å form. Residues from the symmetry-624 
related SH3b domain are denoted by use of a prime (‘), and hydrogen bonds represented as a 625 
dashed line. 626 
 627 
Figure 3. Binding activity of recombinant SH3b-mNeonGreen (SH3b-NG) proteins to 628 
purified S. aureus peptidoglycan 629 
a, peptidogycan binding activities of WT SH3b-NG on S. aureus WT and fem mutants with an 630 
altered peptidoglycan crossbridge. b, peptidogycan binding activities of WT SH3b-NG and 631 
derivatives with mutations in residues involved in the interaction with the G5 ligand. c, 632 
peptidoglycan binding activities of WT SH3b-NG and derivatives with mutations in residues 633 
involved in the interaction with the P4 ligand. The graphs show dose-binding responses whilst 634 
Supplementary Table 2 indicates the amount of PG required for 50% binding (PG50) and the 635 
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corresponding fold change compared to the amount of PG required for 50% binding of the WT 636 
protein as a reference. 637 
 638 
Figure 4. Models for binding of a ligand at two sites 639 
a, schematic representation of a receptor with two sites (R1 and R2), which bind the L1 and L2 640 
ligand sites respectively. L1 and L2 are connected by a flexible linker. b, the flexibility of the 641 
linker allows the R1 site to stay attached, but the R2 site to detach. The effective concentration 642 
of L2 at the R2 site (and thus the cooperativity of binding) will depend on the length and 643 
flexibility of the linker. c, if the linker is too short, it is not possible for the ligand to bind 644 
simultaneously at both R1 and R2. It can alternate between both sites, which will still result in 645 
cooperative binding, though less than in case b. d, a weaker enthalpy of binding (for example 646 
due to the shortness of the linker preventing optimal binding at both sites) can to some extent 647 
be compensated by greater entropy (increased relative motion of ligand and receptor) if there 648 
is weak binding in non-optimal positions. 649 
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Supplementary Table 1. CSPs associated with amino-acid side-chains. 
a Nor malized 1H and 15N chemical shifts in ppm. 
b Value for the 1H 15N chemical shift divided by the average chemical shift.  
c
 Average chemical shift value from all residues when titrated with the corresponding ligand. 
*Slow conformational exchange was reported for the backbone and side-chain of these residues 
showing line broadening and disappearance of the signal at the highest ligand concentrations. 
G5 P4 
Side 
chain 
Normalized a  
(ppm) 
/averageb 
(0.016)c 
Side 
chain 
Normalized a     
 (ppm) 
/averageb 
(0.079) c 
Ws402 0.006 0.383 Ws402 0.039 0.489 
N405s 0.122 7.643 N405s 0.028 0.350 
Ws460 0.005 0.288 Rs427 0.168 2.122 
Ws478 0.004 0.258 Rs433 0.048 0.610 
Ws489 0.001 0.068 Ws460 0.143 1.796 
   
Rs470 0.038 0.484 
   
Rs476 0.015 0.194 
   
Ws478 0.014 0.175 
   
Ws489 0.157 1.982 
P4-G5 GM-P4-G5 
Side 
chain 
Normalized a   
(ppm) 
/averageb 
 (0.069) c 
Side 
chain 
Normalized a     
 (ppm) 
/averageb 
 (0.121) c 
Ws402 0.010 0.143 Ws402 0.126 1.045 
N405s * * N405s 0.174 1.446 
Rs427 * * Rs427 0.226 1.873 
Rs433 0.024 0.348 Rs433 0.096 0.794 
Ws460 0.129 1.879 Ws460 0.199 1.648 
Rs470 0.231 3.367 Rs470 0.216 1.786 
Rs476 0.012 0.175 Rs476 0.071 0.588 
Ws478 0.004 0.058 Ws478 0.021 0.171 
Ws489 0.097 1.417 Ws489 0.143 1.188 
P5-G5-P4-G5 GM-P5-G5-GM-P4-G5 
Side 
chain 
Normalized a   
(ppm) 
/averageb 
 (0.119) c 
Side 
chain 
Normalized a     
 (ppm) 
/averageb 
 (0.057) c 
Ws402 0.059 0.499 Ws402 0.015 0.256 
N405s 0.078 0.653 N405s 0.191 3.343 
Rs427 0.244 2.059 Rs427 0.071 1.247 
Rs433 0.132 1.108 Rs433 0.013 0.235 
Ws460 0.189 1.597 Ws460 0.066 1.165 
Rs470 0.083 0.703 Rs470 0.019 0.334 
Rs476 0.032 0.272 Rs476 0.029 0.513 
Ws478 0.172 1.452 Ws478 0.053 0.925 
Ws489 0.095 0.802 Ws489 0.039 0.689 
Supplementary Table 2. Peptidoglycan binding activities of WT SH3b-NG and 
derivatives showing the amount of PG required for 50% binding (PG50) and the fold 
change as compared to the wild-type domain. 
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Table 3. Bacterial strains and plasmids used in this study 
 
Strains, plasmids  Relevant properties or genotypea Source or reference 
Strains 
Staphylococcus aureus 
SH1000 8325-4 derivate with a restored rsbU allele 46 
NCTC8325 Wild type strain 46 
Escherichia coli  
Lemo21(DE3) BL21 derivative for protein production NEB 
NEB5α Host strain for DNA cloning NEB 
Plasmids 
pET15b Plasmid for the production of proteins with an N-terminal His-tag Novagen 
pET21a Plasmid for the production of proteins with a C-terminal His-tag Novagen 
pET2818 Plasmid for the production of proteins with a C-terminal His-tag lab stock 
pET2817-TEV Plasmid for the production of proteins with an N-terminal cleavable  
His-tag  lab stock 
pET- SH3b pET15b derivative encoding Lss SH3b domain for NMR experiments 38 
pET-Lss pET21a derivative for the expression of the full length Lss lysostaphin 39 
pET-SH3b-TEV pET2817-TEV derivative for the expression of the Lss-SH3b domain  
for X-ray crystallography This study 
pET-SH3b-NG pET2818 derivative for the expression of SH3b-mNeonGreen fusions  This study 
a
 AmpR, resistant to ampicillin; ErmR, resistant to erythromycin 
 
 
Supplementary Table 4. Oligonucleotides used in this study 
Name         Sequence 
N405A_Fw CATGGGATGGAAAACAGCCAAATATGGCACACTATATAAATC 
N405A_Rev TAGTGTGCCATATTTGGCTGTTTTCCATCCCATGGTATATC 
N405A_Fw_Lss TACAGGTTGGAAAACAGCCAAATATGGCACACTATATAAATC 
N405A_Rev_Lss AGTGTGCCATATTTGGCTGTTTTCCAACCTGTATTCGGCGTTG 
T409V_Fw ACAAACAAATATGGCGTGCTATATAAATCAGAGTCAG 
T409V_Rev CTCTGATTTATATAGCACGCCATATTTGTTTGTTTTC 
Y411S_Fw AAATATGGCACACTATCAAAATCAGAGTCAGCTAGCTTC 
Y411S_Rev AGCTGACTCTGATTTTGATAGTGTGCCATATTTGTTTG 
F418V_Fw CAGAGTCAGCTAGCGTCACACCTAATACAGATATAATAAC 
F418V_Rev ATCTGTATTAGGTGTGACGCTAGCTGACTCTGATTTATATAGTG 
N421L_Fw GCTAGCTTCACACCTCTTACAGATATAATAACAAGAACGAC 
N421L_Rev GTTATTATATCTGTAAGAGGTGTGAAGCTAGCTGACTC 
I425A_Fw ACCTAATACAGATATAGCAACAAGAACGACTGGTCCATTTAG 
I425A_Rev CCAGTCGTTCTTGTTGCTATATCTGTATTAGGTGTGAAGCTAG 
T429V_Fw ATAATAACAAGAACGGTTGGTCCATTTAGAAGCATG  
T429V_Rev CTTCTAAATGGACCAACCGTTCTTGTTATTATATCTG 
D450N_Fw CAAACAATTCATTATAATGAAGTGATGAAACAAGAC 
D450N_Rev GTTTCATCACTTCATTATAATGAATTGTTTGACCTG 
E451M_Fw ACAATTCATTATGATATGGTGATGAAACAAGACGGTCATG 
E451M_Rev GTCTTGTTTCATCACCATATCATAATGAATTGTTTGAC 
V452A_Fw TTCATTATGATGAAGCGATGAAACAAGACGGTCATG 
V452A_Rev ACCGTCTTGTTTCATCGCTTCATCATAATGAATTGTTTG 
M453A_Fw CATTATGATGAAGTGGCAAAACAAGACGGTCATGTTTG 
M453A_Rev ATGACCGTCTTGTTTTGCCACTTCATCATAATGAATTG 
M461A_Fw ACGGTCATGTTTGGGCAGGTTATACAGGTAACAGTG 
M461A_Rev TTACCTGTATAACCTGCCCAAACATGACCGTCTTGTTTC 
Y472S_Fw AGTGGCCAACGTATTTCCTTGCCTGTAAGAACATGGAAT 
Y472S_Rev TGTTCTTACAGGCAAGGAAATACGTTGGCCACTGTTAC 
L473A_Fw GGCCAACGTATTTACGCGCCTGTAAGAACATGGAATAAATC 
L473A_Rev CATGTTCTTACAGGCGCGTAAATACGTTGGCCACTGTTAC 
W489L_Fw ACTTTAGGTGTTCTTCTGGGAACTATAAAGGGATCCGGAG 
W489L_Rev TCCCTTTATAGTTCCCAGAAGAACACCTAAAGTATTAGTAG 
W489L_Fw_Lss TACTTTAGGTGTTCTTCTGGGAACTATAAAGCTCGAGCAC 
W489L_Rev_Lss GAGCTTTATAGTTCCCAGAAGAACACCTAAAGTATTAGTAG 
 
 
 
 Table 5.  Data collection and refinement statistics 
 
 Home source set Synchrotron set 
Data collection   
Space group P41212 P41212 
Cell dimensions     
    a, b, c (Å) 47.2, 47.2, 123.1 47.1, 47.1, 122.4 
    α, β, γ  (°)  90, 90, 90 90, 90, 90 
Resolution (Å) 2.5(2.6-2.5)* 1.43 (1.47-1.43) 
Rmerge 12.8(21.5) 5.9 (341.3) 
I / σI 14.3(6.0) 21.6(1.1) 
Completeness (%) 99.6(98.7) 98.9(98.4) 
Redundancy 11.9(8.9) 24.3(24.7) 
 
  
Refinement   
Resolution (Å) 2.5 1.43 
No. reflections 5270 26342 
Rwork / Rfree 25.4/29.0 19.9/23.0 
No. atoms   
    Protein 741 741 
    Ligand/ion 49 52 
    Water 3 24 
B-factors   
    Protein 27.7 43.4 
    Ligand/ion 29.7 44.2 
    Water 17.9 44.3 
R.m.s. deviations   
    Bond lengths (Å) 0.003 0.008 
    Bond angles (°) 1.18 1.49 
A single crystal was used for both data collections. 
 *Values in parentheses are for highest-resolution shell.  
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Supplementary Fig 1. S. aureus PG fragments used as SH3b ligands. The structure of each 
ligand, its name and method of preparation are indicated.
Supplementary Fig 2. Fully assigned 1H- 15N HSQC spectrum of the lysostaphin SH3b apo
domain (residues 402-493). Assigned backbone amide resonances are shown. Side-chain 
resonances of tryptophan, glutamine and asparagine residues are indicated in green.
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Supplementary Figure 3. Chemical shift perturbation (CSP) analysis of the SH3b protein
interactions with a set of six different PG fragments derived from S. aureus. Histograms of the
observed CSP values calculated as ∆δ=(∆δH²+(0.154x∆δN)²), as a function of the amino acid sequence
are shown. The y-axis represents the ratio between individual CSPs and the average CSP (taking all
residues into account). An arbitrary threshold of 2 was chosen. Residues associated with CSPs above
the threshold using G5 as a ligand are in red, those with CSPs above the threshold using P4 as a ligand
are in green. Titrations were carried out using 50 µM of protein and G5 (a), P4 (b), P4-G5 (c), P5-G5-
P4 (e) and GM-P5-G5-GM-P4-G5 (f). 0, 0.33, 0.66, 1, 2, 4, 8, 16, 32, and 64 equivalents of ligand
were used in (a)-(c); 16 equivalents in (d), and only 4 equivalents in (e) as protein aggregation
occurred.
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Supplementary Fig 4. Comparison of ligand-binding pocket to other SH3b structures and
SH3 superfamily members. a, Lysostaphin SH3b domain in complex with the P4-G5 ligand. b,
Superimposition of the structure shown in A onto the ALE-1 structure (1r77, two symmetry-related
monomers orange and yellow). The P4-G5 ligand occupies the same space as an affinity
purification tag (helical turn, N-terminus labelled). c, Superimposition of the structure shown in A
onto the phi7917 structure (5D76, tan). Ligand P3(K)-P4(A) are sterically equivalent to tag
residues K269 and V268, respectively. The phi7917 ligand (L-Ala-D-Gln) is positioned with its
peptide bond over the P3-P4 peptide. d, Sequence alignment of Lysostaphin SH3b (SH3_5
subfamily) with ALE-1 (SH3_5) and the two tandem domains of Clostridium phage phiSM101
(4krt, SH3_3 subfamily), G5 and P4-ligating residues annotated with magenta and green block
below text, respectively.
e, Weblogo (Crooks et al., 2004) plot of sequence consensus of SH3_4 subfamily, identifying
features with likely equivalence to SH3_3 and SH3_5 alignment: NxR (position 6-8, match lss
I425-R427), W (36, match to W460), GxxGW (43-47, match to G468-Y472) and LWG (53-55,
match to L488-G490). No structures are currently available for SH3_4 proteins, but structural
comparison between Lss/ALE-1 and 4krt confirms conservation of the P-stem D-Ala(4)-
carboxylate pocket.
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Supplementary Fig 6. Mutagenized residues at the SH3b:P4-G5 interaction interface. The 
representation is identical to figure 2, but displaying all residues selected for mutation in stick form 
(to avoid confusion, residues are only displayed once, from the SH3b domain that places them 
closest to the ligand).
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Supplementary Fig 7. Comparison of the enzymatic activity of lysostaphin (Lss) recombinant
proteins containing mutations in the SH3b domain. Three independent series of purifications
were carried out (left, middle and right panels), each including a wild-type protein as a control.
Five µl corresponding to serial dilutions of recombinant Lss proteins were spotted on agar plates
containing autoclaved S. aureus cells (final OD600 of 1) as a substrate. Lytic activities were
detected as clearing zones and compared by determining the lowest amount of enzyme giving a
detectable digestion of the substrate.
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Supplementary Fig 8. Amino acid sequences of the recombinant wild-type proteins used in
this study. In each case, both the plasmid encoding the recombinant SH3b protein (in brackets)
and the experiment it was used for are indicated. The SH3b domain is in red, amino acids encoded
by the expression vector in grey, linker in blue and mNeonGreen in green. The TEV cleavage site
is indicated by an arrow.
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Supplementary Fig 9. SDS-PAGE analysis of recombinant proteins used for NMR studies.
a, doubly labelled SH3b domain for spectrum assignment described in Supplementary Fig. 2.
b, singly labelled His-tagged SH3b domain used for NMR titrations with ligands described in Fig.
1 and Supplementary Fig. S3. c, singly labelled His-tagged derivatives used for the mutational
analysis of the SH3b domain described in Supplementary Fig. 5.
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Supplementary Fig 10. SDS-PAGE analysis of recombinant proteins used for X-ray
crystallography. The different steps of the purification are described. The final purification
product corresponding to the SH3b domain without any His-tag was used for co-crystallisation
experiments.
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Supplementary Fig 11. SDS-PAGE analysis of recombinant SH3bp-mNeonGreen fusion
proteins used for PG binding assays. a, mNeonGreen control and SH3b mutants harbouring
mutations in the residues involved in the interaction with G5 ligands. b, SH3b mutants harbouring
mutations in the residues involved in the interaction with P4 ligands. The amount of protein per
binding assay was adjusted using the fluorescent signal intensity of the full-length protein.
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Supplementary Fig 12. SDS-PAGE analysis of recombinant SH3bp-mNeonGreen fusion
proteins used for PG binding assays. a, mNeonGreen control and SH3b mutants harbouring
mutations in the residues involved in the interaction with G5 ligands. b, SH3b mutants harbouring
mutations in the residues involved in the interaction with P4 ligands. The amount of protein per
binding assay was adjusted using the fluorescent signal intensity of the full-length protein.
